Covaccine’ is also effective against multiple variants and double mutant strains: ICMR study

At a time when the number of corona cases in the country has increased alarmingly fast, the government is focused on getting more and more corona vaccine to more people in the country.

Covaxin: Minor relief amid disturbing news during the Kovid epidemic can be felt by the fact that corona’s vaccine ‘covaxine’ is effective on multiple variants and double mutant strains. This conclusion has been drawn in the study of the Indian Council of Medical Research (ICMR). In a tweet from ICMR, the study states that covicin is also effective against the multi variants of SARS-CoV-2 and double mutant strains. The covaxin is a indigenously manufactured corona vaccine and is being marketed by ICMR and Bharat Biotech. Has developed. At a time when the number of corona cases in the country has increased alarmingly fast, the government is focused on getting more and more corona vaccine to more people in the country.

It is worth mentioning that Covaccine is a domestically produced Corona vaccine and has been developed by ICMR and Bharat Biotech. At a time when the number of corona cases in the country has increased alarmingly fast, the government is focused on getting more and more corona vaccine to more people in the country. The third phase of corona vaccination will start from May 1 and people 18 or older will be vaccinated in it. Bharat Biotech will produce 30 million doses of the Kovid-19 vaccine ‘covaxine’ next month to support the vaccination campaign in the country. Krishna Alla, Chairman and Managing Director of the company gave this information. In March, the company produced 15 million doses of covaccin. The vaccine manufacturer said in a statement that it has increased the annual production capacity of covaccine to 700 million doses.

Alla’s statement comes at a time when Prime Minister Narendra Modi has asked vaccine manufacturers to increase vaccine production, in which all Indians can be vaccinated in the shortest possible time. The government has also allowed Serum Institute of India and Bharat Biotech to make an advance payment of Rs 4,500 crore to increase the supply in future. Addressing a program, Alla said that the company is going to start two new vaccine plants in Bengaluru. The company initially started production from a plant. The company now has four plants in Hyderabad. He said, “Last month we produced 1.5 crore doses. This month we are producing 20 million doses. Next month we will produce 30 million doses. After that seven to seven and a half crore doses will be produced. ”